Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Nivolumab (BMS-936558)

13 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    ECOGMDS1609

    10/19/2017

    DART: Dual Anti-Ctla-4 and Anti-Pd-1 Blockade in Rare Tumors

    Treatment

    VICCTHO1729

    09/14/2017

    A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination with Nivolumab or Nivolumab and Ipilimumab for Adults with Extensive- Stage Small Cell Lung Cancer

    Treatment

    VICCTHO1718

    08/17/2017

    Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CheckMate 816: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 816)

    Treatment

    VICCURO16101

    08/10/2017

    A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors

    Treatment

    VICCMD1710

    08/03/2017

    A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination with a PD-1 Inhibitor and Chemotherapy in Subjects with Advanced or Metastatic Solid Tumors (ECHO-207)

    Treatment

    VICCTHO16139

    06/13/2017

    A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

    Treatment

    ECOGUROEA8143

    06/09/2017

    PHIII Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy.

    Treatment

    VICCNEU1644

    04/28/2017

    A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma

    Treatment

    VICCNEU1688

    04/28/2017

    A Randomized Phase 2 Single Blind Study of Temozolomide Plus Radiation Therapy Combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (Tumor O6-methylguanine DNA methyltransferase) Glioblastoma

    Treatment

    VICCMD15128

    01/16/2017

    A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers

    Treatment

    VICCGI1655

    12/14/2016

    A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

    Treatment

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    ECOGTHOS1400

    04/02/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer


    Print this page for your doctor